All clear for Nobel Biocare

The Swedish Medical Products Agency has said that based on new data and following a meeting yesterday, it sees no reason for Nobel Biocare AG to withdraw its dental implant Nobel Direct from the market.

Nobel Biocare shares have come under pressure recently due to safety concerns about the product.

Participants from Medical Products Agency, Nobel Biocare and clinicians met yesterday for a discussion regarding the amount of bone resorption for the Nobel Direct dental implant.

“Based on the data presented at the meeting the Medical Products Agency has found no reason to withdraw the implant from the market,” it said today.

Nobel Biocare shares rose by almost 6% following the news.


Sweden’s Meda denies India merger rumours

Swedish drug maker Meda, reported to be a takeover target by Indian group Sun Pharmaceutical, denied on Wednesday that merger talks were under way.

Sweden's Meda denies India merger rumours

Last week, the Wall Street Journal reported, citing anonymous sources, that Mumbai-based generic drug firm Sun Pharma was in discussions with banks to finance the deal.

“Due to the recent speculation in the press and news media concerning Meda merging with another pharmaceutical company, we have decided to inform the market that there are currently no such discussions,” Meda said in a statement.

Meda added that it does not generally comment on “speculation” and that issuing the statement was an “exception to its policy.”

Stockholm-based Meda, a maker of branded generic prescription and over-the-counter drugs, is listed on the Swedish stock exchange. Sun Pharma previously declined to comment on what it called “media conjecture”.

Shares of Sun Pharma, which has a market capitalisation of nearly $20 billion — the highest of all Indian generics firms — closed up nearly two percent at 1,038.3 rupees after Meda’s denial which eased investor concerns over the deal’s cost.

AFP/The Local/dl

Follow The Local on Twitter